Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in:

16.08.2024 | Nuclear Medicine

Glucose metabolic rate from four-dimensional [18F]FDG PET/CT to differentiate sarcoid lesions from malignant lesions

verfasst von: Akihiro Inoue, Michinobu Nagao, Koichiro Kaneko, Atsushi Yamamoto, Yurie Shirai, Ohno Toshihiro, Akiko Sakai, Risa Imakado, Shuji Sakai

Erschienen in: European Radiology | Ausgabe 2/2025

Einloggen, um Zugang zu erhalten

Abstract

Objectives

On 18F-Fludeoxyglucose (FDG) PET/CT, active sarcoid lesions are often difficult to differentiate from malignant lesions. We investigated the potential of the glucose metabolic rate (MRglc, mg/min/100 mL), a new quantification of glucose metabolic kinetics derived from direct reconstruction based on linear Patlak analysis, to distinguish between sarcoidosis and malignant lesions.

Materials and methods

A total of 100 patients with cardiac sarcoidosis (CS) and 67 patients with cancer who underwent four-dimensional FDG PET/CT were enrolled. The lesions with a standardized uptake value (SUV) ≥ 2.7 on the standard scan were included as active lesions in the analysis. SUV and MRglc were derived using data acquired between 30 min and 50 min on four-dimensional FDG PET/CT. The mean value in the volume of interest (size 1.5 cm3) was measured. The diagnostic performance of sarcoidosis using MRglc and SUV was evaluated using receiver-operating-characteristic (ROC) analysis.

Results

A total of 90 sarcoidosis lesions from 44 CS patients (18 males, 63.4 ± 12.2 years) and 87 malignant lesions from 57 cancer-bearing patients (32 males, 65 ± 14 years) were analyzed. SUV and MRglc for sarcoid lesions were significantly lower than those for malignant lesions (SUV, 4.98 ± 2.00 vs 6.21 ± 2.14; MRglc, 2.52 ± 1.39 vs 3.68 ± 1.61; p < 0.01). ROC analysis indicated that the ability to discriminate sarcoid patients from those with malignancy yielded areas under the curves of 0.703 and 0.754, with sensitivities of 64% and 77% and specificities of 75% and 72% for SUV 5.025 and MRglc 2.855, respectively.

Conclusion

MRglc was significantly lower in sarcoid lesions than malignant lesions, and improved sarcoid lesions identification over SUV alone.

Clinical relevance statement

MRglc improves sarcoid lymph node identification over SUV alone and is expected to shorten the examination time by eliminating delayed scans.

Key Points

  • Active sarcoid lesions are sometimes associated with FDG accumulation and should be differentiated from malignant lesions.
  • SUV and metabolic rate of glucose (MRglc) strongly positively correlated, and MRglc could differentiate sarcoid and malignant lesions.
  • MRglc allows for accurate evaluation and staging of malignant lesions.

Graphical Abstract

Literatur
1.
Ungprasert P, Ryu JH, Matteson EL (2019) Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes 3:358–375CrossRefPubMedPubMedCentral
2.
Cherrett C, Lee W, Bart N, Subbiah R (2023) Management of the arrhythmic manifestations of cardiac sarcoidosis. Front Cardiovasc Med 10:1–10CrossRef
3.
Tateishi E, Kiso K (2018) [18F]FDG PET/CT for detecting cardiac sarcoidosis. Ann Nucl Cardiol 4:151–154CrossRef
4.
Brudin LH, Valind SO, Rhodes CG et al (1994) Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med Mol Imaging 21:297–305CrossRef
5.
6.
Shetty A, Carter JD (2011) Sarcoidosis mimicking lymphoma on FDG-PET imaging. Radiol Case Rep 6:409CrossRefPubMed
7.
Tamaki N, Hirata K, Kotani T et al (2023) Four‐dimensional quantitative analysis using FDG‐PET in clinical oncology. Jpn J Radiol 41:831–842CrossRefPubMedPubMedCentral
8.
Rahmim A, Lodge MA, Karakatsanis NA et al (2019) Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging 46:501–518CrossRefPubMed
9.
Dias AH, Pedersen MF, Danielsen H, Munk OL, Gormsen LC (2021) Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body [18F]FDG PET/CT scans. Eur J Nucl Med Mol Imaging 48:837–850CrossRefPubMed
10.
Dimitrakopoulou-Strauss A, Pan L, Strauss LG (2012) Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging 12:283–289CrossRefPubMedPubMedCentral
11.
Dias AH, Hansen AK, Munk OL, Gormsen LC (2022) Normal values for [18F]FDG uptake in organs and tissues measured by dynamic whole-body multiparametric FDG PET in 126 patients. EJNMMI Res 12:1–14CrossRef
12.
Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H (2019) Does whole-body Patlak [18F]FDG PET imaging improve lesion detectability in clinical oncology? Eur Radiol 29:4812–4821CrossRefPubMed
13.
Chen X, Xu X, Chrysikos S, Zhao M, Zhou Y (2022) Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study. Transl Lung Cancer Res 11:1926–1935CrossRefPubMedPubMedCentral
14.
Koo HJ, Kim MY, Shin SY et al (2015) Evaluation of mediastinal lymph nodes in sarcoidosis, sarcoid reaction, and malignant lymph nodes using CT and FDG-PET/CT. Medicine (Baltimore) 94:e1095CrossRefPubMed
15.
Kaneko K, Nagao M, Yamamoto A, Sakai A, Sakai S (2023) FDG uptake patterns in isolated and systemic cardiac sarcoidosis. J Nucl Cardiol 30:1065–1074CrossRefPubMed
16.
van Sluis J, van Snick JH, Brouwers AH et al (2022) Shortened duration whole body [18F]FDG PET patlak imaging on the biograph vision Quadra PET/CT using a population-averaged input function. EJNMMI Phys 9:1–14
17.
Dias AH, Smith AM, Shah V, Pigg D, Gormsen LC, Munk OL (2022) Clinical validation of a population-based input function for 20-min dynamic whole-body [18F]FDG multiparametric PET imaging. EJNMMI Phys 9:1–18CrossRef
18.
Dimitrakopoulou-Strauss A, Pan L, Sachpekidis C (2022) Parametric imaging with dynamic PET for oncological applications: protocols, interpretation, current applications and limitations for clinical use. Semin Nucl Med 52:312–329CrossRefPubMed
19.
Patlak CS, Blasberg RG, Fenstermacher JD (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb Blood Flow Metab 5:584–590CrossRefPubMed
20.
Naganawa M, Gallezot JD, Shah V et al (2020) Assessment of population-based input functions for Patlak imaging of whole body dynamic [18F]FDG PET. EJNMMI Phys 7:67CrossRefPubMedPubMedCentral
21.
Kaneko K, Nagao M, Yamamoto A et al (2024) Patlak reconstruction using dynamic 18F-FDG PET imaging for evaluation of malignant liver tumors a comparison of HCC, ICC, and metastatic liver tumors. Clin Nucl Med 39:116–123CrossRef
22.
Osborne MT, Hulten EA, Singh A et al (2014) Reduction in [18F] fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 21:166–174CrossRefPubMed
23.
Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24S–42SCrossRefPubMed
24.
Jadvar H, Alavi A, Gambhir SS (2009) [18F]FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 50:1820–1827CrossRefPubMed
25.
Kaneko K, Sadashima S, Irie K et al (2013) Assessment of FDG retention differences between the FDG-avid benign pulmonary lesion and primary lung cancer using dual-time-point FDG-PET imaging. Ann Nucl Med 27:392–399CrossRefPubMed
26.
Coelho RG, Calaça IC, Celestrini DM et al (2015) Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma. Oncotarget 6:29375–29387CrossRefPubMedPubMedCentral
27.
van den Hoff J, Oehme L, Schramm G et al (2013) The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res 23:77CrossRef
Metadaten
Titel
Glucose metabolic rate from four-dimensional [18F]FDG PET/CT to differentiate sarcoid lesions from malignant lesions
verfasst von
Akihiro Inoue
Michinobu Nagao
Koichiro Kaneko
Atsushi Yamamoto
Yurie Shirai
Ohno Toshihiro
Akiko Sakai
Risa Imakado
Shuji Sakai
Publikationsdatum
16.08.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2025
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-024-11022-w

Weitere Artikel der Ausgabe 2/2025

RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

  • Hepatobiliary-Pancreas

Are there features that can predict the unresectability of pleural mesothelioma?

  • Chest

ESR Bridges: imaging and treatment of extranodal spread in head and neck cancer—a multidisciplinary view

  • Commentary

Dilated lenticulostriate artery on whole-brain vessel wall imaging differentiates pathogenesis and predicts clinical outcomes in single subcortical infarction

  • Magnetic Resonance

Deep learning model based on contrast-enhanced ultrasound for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma

  • Ultrasound

Breaking new ground in COPD imaging: 3D-PREFUL MRI versus traditional techniques

  • Commentary

Neu im Fachgebiet Radiologie

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Röntgen-Thorax oder LDCT fürs Lungenscreening nach HNSCC?

Personen, die an einem Plattenepithelkarzinom im Kopf-Hals-Bereich erkrankt sind, haben ein erhöhtes Risiko für Metastasen oder zweite Primärmalignome der Lunge. Eine Studie hat untersucht, wie die radiologische Überwachung aussehen sollte.

Statine: Was der G-BA-Beschluss für Praxen bedeutet

Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise